457 related articles for article (PubMed ID: 25475110)
1. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
3. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.
Cook NR; Lee IM; Zhang SM; Moorthy MV; Buring JE
Ann Intern Med; 2013 Jul; 159(2):77-85. PubMed ID: 23856681
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
5. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Dorresteijn JA; Visseren FL; Ridker PM; Paynter NP; Wassink AM; Buring JE; van der Graaf Y; Cook NR
Eur Heart J; 2011 Dec; 32(23):2962-9. PubMed ID: 22090661
[TBL] [Abstract][Full Text] [Related]
7. Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
Selak V; Kerr A; Poppe K; Wu B; Harwood M; Grey C; Jackson R; Wells S
JAMA; 2018 Jun; 319(24):2507-2520. PubMed ID: 29946729
[TBL] [Abstract][Full Text] [Related]
8. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
Lin KJ; De Caterina R; García Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
10. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis.
Selak V; Jackson R; Poppe K; Wu B; Harwood M; Grey C; Pylypchuk R; Mehta S; Choi YH; Kerr A; Wells S
Ann Intern Med; 2019 Oct; 171(8):529-539. PubMed ID: 31525775
[TBL] [Abstract][Full Text] [Related]
11. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
[TBL] [Abstract][Full Text] [Related]
12. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
[TBL] [Abstract][Full Text] [Related]
13. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
[TBL] [Abstract][Full Text] [Related]
14. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T; Miller T; Ko S
Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
[TBL] [Abstract][Full Text] [Related]
15. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
[TBL] [Abstract][Full Text] [Related]
16. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
Dehmer SP; O'Keefe LR; Evans CV; Guirguis-Blake JM; Perdue LA; Maciosek MV
JAMA; 2022 Apr; 327(16):1598-1607. PubMed ID: 35471506
[TBL] [Abstract][Full Text] [Related]
17. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
18. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
20. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
